Table 2 Carrier frequency of KIR+HLA class I ligand combinations in breast cancer patients and controls.
KIR- HLA combination | Healthy controls (n = 278) | Breast cancer | Comparison | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
All (n = 162) | Advanced (n = 44) | Early (n = 70) | All versus controls | Advanced versus controls | ||||||||
p value | OR (95% CI) | p value | OR (95% CI) | |||||||||
%F | (N +) | %F | (N +) | %F | (N +) | |||||||
Inhibitory KIR + HLA class I ligand | ||||||||||||
2DL1 + C2 + | 74.7 | (192/256) | 67.9 | (93/135) | 79.5 | (31/38) | 57.9 | (33/56) | ||||
2DL2 + 2DL3 + C1 + | 34.6 | (92/256) | 32.7 | (50/140) | 35.7 | (15/38) | 29.7 | (19/56) | ||||
3DL1 + Bw4 + | 60.6 | (143/233) | 50.8 | (62/116) | 58.8 | (20/32) | 51.0 | (26/48) | ||||
3DL2 + A3/A11 + | 40.0 | (50/125) | 42.4 | (39/92) | 31.8 | (7/22) | 37.8 | (14/37) | ||||
Activating KIR + HLA class I ligand | ||||||||||||
2DS1 + C2 + | 26.9 | (73/256) | 36.1 | (53/135) | 52.4 | (22/38) | 21.0 | (13/56) | 0.001 | 2.98 (1.54 to 5.79) | ||
3DS1 + Bw4 + | 17.7 | (46/233) | 25.9 | (37/116) | 29.3 | (12/32) | 18.6 | (11/48) | 0.008 | 2.6 (1.26 to 5.39) | ||
Inhibitory KIR + Activating KIR + HLA class I ligand | ||||||||||||
2DL1 + C2 + 2DS1 + | 26.6 | (72/256) | 34.5 | (51/135) | 52.4 | (22/38) | 19.0 | (2/56) | 0.001 | 3.04 (1.56 to 5.89) | ||
2DL1 + C2 + 2DS1 − | 45.5 | (120/256) | 27.8 | (42/135) | 22.0 | (9/38) | 32.8 | (21/56) | 0.0004 | 0.46 (0.3 to 0.71) | 0.005 | 0.34 (0.15 to 0.73) |
3DL1 + Bw4 + 3DS1 + | 15.6 | (41/233) | 20.1 | (30/116) | 29.3 | (12/32) | 14.5 | (9/48) | 0.033 | 2.23 (1.05 to 4.72) | ||
3DL1 + Bw4 + 3DS1- | 40.5 | (102/233) | 23.7 | (32/116) | 21.6 | (8/32) | 28.8 | (17/48) | 0.001 | 0.46 (0.28 to 0.73) | 0.027 | 0.41 (0.18 to 0.92) |
2DL1 + C2 + 3DL1 + Bw4 + 2DS1 + 3DS1 + | 11.5 | (30/233) | 12.3 | (19/116) | 19.5 | (8/32) | 4.6 | (3/48) | ||||
2DL1 + C2 + 3DL1 + Bw4 + 2DS1 − 3DS1 − | 25.9 | (66/233) | 12.8 | (19/116) | 12.5 | (5/32) | 16.1 | (10/48) | 0.002 | 0.42 (0.24 to 0.73) |